Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H, Matsuda T, Mizuno S, Takahashi T, Fuchida SI, Hanamura I, Kataoka K, Tsukada N, Matsumoto M, Hangaishi A, Doki N, Uchida N, Sawa M, Maruyama Y, Kurahashi S, Nagafuji K, Harazaki Y, Kako S, Iida S, Ichinohe T, Kanda Y, Atsuta Y, Sunami K; Multiple Myeloma Working Group in the Japanese Society for Transplantation and Cellular Therapy.
Takamatsu H, et al. Among authors: kanda y.
Haematologica. 2023 Dec 1;108(12):3399-3408. doi: 10.3324/haematol.2023.283202.
Haematologica. 2023.
PMID: 37470160
Free PMC article.